AVANT BIO

New York, New York
Firm Location:New York, New York • United Kingdom
Investor Firms That Co-Invest with AVANT BIO
AVANT BIO Team
Photo of Jessica Davis, Principal at AVANT BIO
Jessica Davis
AVANT BIO·Principal
Sweet spot: $15.0M
Range: $1M - $50.0M
Investors in New York (NY)
Investors in Diagnostics (Seed), Investors in Digital Health (Seed), Investors in Consumer Health (Seed), Investors in Diagnostics (Seed), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in Consumer Health (Seed), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in BioTech (Series A), Investors in Consumer Health (Series A), Investors in Health IT (Series A), Investors in Digital Health (Series A), Investors in Consumer Health (Series A), Investors in Digital Health (Series A), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Consumer Health (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in Consumer Health (Series B), Investors in New York City (Other Lists)
Photo of Ole Henrik Bang-Andreasen, Analyst at AVANT BIO
Ole Henrik Bang-Andreasen
AVANT BIO·Analyst
Sweet spot: $15.0M
Range: $1M - $50.0M
Investors in United Kingdom
Investors in Therapeutics (Seed), Investors in Diagnostics (Seed), Investors in Medical Devices (Seed), Investors in BioTech (Seed), Investors in Digital Health (Seed), Investors in Health IT (Seed), Investors in Pharmaceuticals (Seed), Investors in Diagnostics (Series A), Investors in Medical Devices (Series A), Investors in Digital Health (Series A), Investors in Health IT (Series A), Investors in Therapeutics (Series A), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in Therapeutics (Series B), Investors in Diagnostics (Series B), Investors in Medical Devices (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in Pharmaceuticals (Series B)
Photo of Daniella Kranjac, General Partner at AVANT BIO
Daniella Kranjac
AVANT BIO·General Partner
Sweet spot: $5.0M
Range: $3.0M - $10.0M
Investors in Switzerland, Investors in United Kingdom, Investors in Europe, Investors in Canada, Investors in United States
Investors in Consumer Health (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in Health & Hospital Services (Seed), Investors in Consumer Health (Seed), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in Consumer Health (Series A), Investors in Digital Health (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Consumer Health (Series A), Investors in BioTech (Series A), Investors in Digital Health (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in Consumer Health (Series B), Investors in Health & Hospital Services (Series B), Investors in BioTech (Series B), Investors in Consumer Health (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Canada (Other Lists), Investors in Female Investors (Other Lists), Investors in Diverse Investors (Other Lists), Investors in Investors who were founders (Other Lists), Investors in Investors who invested in female founders (Other Lists), Investors in Investors who invested in diverse founders (Other Lists), Investors in New York City (Other Lists)
Photo of Sebastien Latapie, Principal at AVANT BIO
Sebastien Latapie
AVANT BIO·Principal
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY)
Photo of Peter Lee, Partner at AVANT BIO
Peter Lee
AVANT BIO·Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY)